INJECTABLE ASTHMA DRUG RESLIZUMAB APPROVED BY EC

摘要

The European Commission has approved a marketing authorisation for reslizumab (Teva Pharmaceutical Industries' Cinqaero), an injectable treatment for severe asthma The decision follows a recommendation in June 2016 by the European Medicines Agency's Committee for Medicinal Products for Human Use that marketing authorisation be granted for use as an add-on therapy in adult patients with severe eosinophilic asthma inadequately controlled despite high-dose inhaled corticosteroids plus another medicinal product. The drug was approved for use in the United States in March 2016.